|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,962.50 GBX | +2.13% |
|
+3.18% | +7.56% |
| 02:02am | Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal | RE |
| Jun. 10 | Intron Health Upgrades GSK to Hold Rating, Lifts PT | MT |
| Market Cap | 76.71B 102B 88.81B 81.86B 143B 9,799B 146B 977B 378B 4,723B 384B 376B 16,423B | P/E Ratio 2026 * |
12.4x | P/E Ratio 2027 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise Value | 90.94B 121B 105B 97.05B 170B 11,617B 173B 1,158B 448B 5,600B 455B 446B 19,470B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.48x |
| Free-Float |
92.3% | Yield 2026 * |
3.64% | Yield 2027 * | 3.8% |
Last Transcript: GSK plc
| 1 day | +2.06% | ||
| 1 week | +3.18% | ||
| Current month | +4.31% | ||
| 1 month | +6.40% | ||
| 3 months | -5.01% | ||
| 6 months | +7.77% | ||
| Current year | +7.56% |
| 1 week | 1,839 |  | 1,973 |
| 1 month | 1,690 | | 2,191 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| Jun. 07 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| May. 21 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| May. 14 | Buy | Director | 2,301 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.13% | +3.18% | +28.86% | +42.85% | 103B | |
| +1.53% | +2.63% | +42.82% | +159.33% | 1,013B | |
| +0.50% | +5.12% | +54.48% | +50.00% | 574B | |
| +0.26% | +0.34% | +17.86% | +63.88% | 397B | |
| -0.37% | +4.97% | +21.24% | +15.95% | 324B | |
| +0.85% | +0.18% | +24.50% | +14.78% | 280B | |
| +2.10% | +4.92% | +25.30% | +33.80% | 273B | |
| +3.83% | +1.51% | +20.22% | +61.40% | 182B | |
| -0.19% | -0.46% | -45.32% | -48.35% | 194B | |
| +3.37% | -2.76% | +14.92% | +61.33% | 151B | |
| Average | +1.36% | +2.76% | +20.49% | +45.50% | 349.14B | |
| Weighted average by Cap. | +1.12% | +3.98% | +29.36% | +71.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.81B 45.1B 39.14B 36.08B 63.16B 4,319B 64.48B 430B 167B 2,082B 169B 166B 7,238B | 35.48B 47.34B 41.08B 37.87B 66.3B 4,533B 67.68B 452B 175B 2,185B 178B 174B 7,598B |
| Net income | 6.26B 8.35B 7.24B 6.68B 11.69B 799B 11.93B 79.65B 30.84B 385B 31.33B 30.66B 1,340B | 6.66B 8.89B 7.71B 7.11B 12.44B 851B 12.7B 84.79B 32.83B 410B 33.36B 32.64B 1,426B |
| Net Debt | 14.23B 18.99B 16.48B 15.19B 26.59B 1,818B 27.14B 181B 70.14B 876B 71.28B 69.74B 3,047B | 11.2B 14.94B 12.96B 11.95B 20.92B 1,430B 21.35B 143B 55.18B 689B 56.07B 54.86B 2,397B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-11 | 1,962.50 p | +2.13% | 5,560,311 |
| 26-06-10 | 1,921.50 p | +0.95% | 6,411,680 |
| 26-06-09 | 1,903.50 p | -0.50% | 9,722,638 |
| 26-06-08 | 1,913.00 p | -1.29% | 4,170,780 |
| 26-06-05 | 1,938.00 p | +1.89% | 6,351,418 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
